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1. INTRODUCTION {#cas14207-sec-0002}
===============

Multiple myeloma (MM), the second most common hematological malignancy, is an incurable and fatal disease that eventually recurs as a result of intrinsic and/or acquired drug resistance despite recent therapeutic advances.[1](#cas14207-bib-0001){ref-type="ref"}, [2](#cas14207-bib-0002){ref-type="ref"} MM is characterized by the close relationship between malignant plasma cells and stromal and endothelial cells in the bone marrow microenvironment, which secrete growth factors, such as interleukin‐6 (IL‐6) and insulin‐like growth factor 1 (IGF1), thereby stimulating survival pathways, including MEK/ERK, JAK/STAT and PI3K/Akt, which promote myeloma cell growth, survival and drug resistance, respectively.[2](#cas14207-bib-0002){ref-type="ref"}, [3](#cas14207-bib-0003){ref-type="ref"}, [4](#cas14207-bib-0004){ref-type="ref"} The PI3K/Akt pathway is constitutively activated in a significant proportion of myeloma patients[3](#cas14207-bib-0003){ref-type="ref"}; despite the paucity of activating mutations in the pathway downstream effectors, or inactivating mutations in the tumor suppressor *PTEN*.[5](#cas14207-bib-0005){ref-type="ref"}, [6](#cas14207-bib-0006){ref-type="ref"} PI3K/Akt targets multiple downstream effectors by activating and inactivating phosphorylation of, for example, mTORC1 and FOXO transcription factors (TFs), respectively, thereby maintaining cell proliferation and survival.[7](#cas14207-bib-0007){ref-type="ref"} A plethora of studies have extensively investigated Akt inhibitors, alone or in combination, in multiple phase I and II clinical trials; however, the outcomes in hematological malignancies have been largely unsatisfactory,[8](#cas14207-bib-0008){ref-type="ref"} emphasizing the need for critical preclinical evaluations of Akt inhibitors in combination with other targeted therapies.[9](#cas14207-bib-0009){ref-type="ref"} TAS‐117, a potent and selective non‐competitive Akt inhibitor against MM,[10](#cas14207-bib-0010){ref-type="ref"} is currently in ongoing phase II clinical trials against solid tumors (<https://www.clinicaltrials.jp/cti-user/common/Top.jsp> JapicCTI‐152780). However, its preclinical evaluation in hematological malignancies warrants further research to achieve optimum combination outcomes.

Polycomb repressive complex 2 (PRC2) is an epigenetic modulator that tri‐methylates histone H3 at lysine 27 (H3K27me3) through its catalytic components (enhancer of zeste 2 (EZH2) and its closely related homolog EZH1) to silence the transcription of its target genes.[11](#cas14207-bib-0011){ref-type="ref"} *EZH2* is aberrantly overexpressed or subjected to gain‐of‐function mutations in various malignant tumors,[12](#cas14207-bib-0012){ref-type="ref"} including hematological malignancies.[13](#cas14207-bib-0013){ref-type="ref"}, [14](#cas14207-bib-0014){ref-type="ref"} In MM, *EZH2* is overexpressed and correlates not only with the development of asymptomatic monoclonal gammopathy of undetermined significance (MGUS) to active full‐blown myeloma[13](#cas14207-bib-0013){ref-type="ref"}, [15](#cas14207-bib-0015){ref-type="ref"} but also with disease prognosis and poor survival,[16](#cas14207-bib-0016){ref-type="ref"} which emphasizes the importance of targeting EZH2 in the treatment of MM. Preclinical investigations on "selective" EZH2 inhibitors involved some of them in clinical trials against various tumors, including MM.[12](#cas14207-bib-0012){ref-type="ref"} However, neither the compensatory role of EZH1[17](#cas14207-bib-0017){ref-type="ref"}, [18](#cas14207-bib-0018){ref-type="ref"} nor its complementary effects on the action of EZH2[19](#cas14207-bib-0019){ref-type="ref"}, [20](#cas14207-bib-0020){ref-type="ref"}, [21](#cas14207-bib-0021){ref-type="ref"} can be ignored. Moreover, the inhibition of EZH2 alone was not sufficient to completely disrupt the oncogenic functions of PRC2 in different malignancies, including acute myeloid leukemia[21](#cas14207-bib-0021){ref-type="ref"} and MM,[19](#cas14207-bib-0019){ref-type="ref"}, [20](#cas14207-bib-0020){ref-type="ref"} pointing to the benefit of targeting both EZH2 and EZH1 in PRC2‐dependent cancers.

The interplay between signaling cascades and epigenetic modulators is poorly understood in MM. The majority of signal transduction pathways need to eventually be translated into specific transcriptional signatures, which, in part, are achieved through the modulation of chromatin modifiers, including PRC2 components, thereby enhancing or repressing transcription at specific loci. Although some of these interactions have been described in solid tumors,[22](#cas14207-bib-0022){ref-type="ref"}, [23](#cas14207-bib-0023){ref-type="ref"}, [24](#cas14207-bib-0024){ref-type="ref"} limited information is currently available on this crosstalk in hematological malignancies, including MM. Given the importance of PRC2 as a therapeutic target in MM, we aimed to investigate the mechanisms by which Akt inhibition may impact PRC2 function and highlight whether targeting both EZH2 and EZH1 together with Akt inhibition is a promising treatment strategy for MM.

2. MATERIALS AND METHODS {#cas14207-sec-0003}
========================

2.1. Reagents {#cas14207-sec-0004}
-------------

TAS‐117, trans‐3‐amino‐1methyl‐3‐\[4‐(3‐phenyl‐5H‐imidazo \[1,2‐c\]pyrido\[3,4‐e\]\[1,3\]oxazin‐2‐yl)phenyl\]‐cyclobutanol, was obtained from Taiho Pharmaceutical Co., Ltd. and diluted in DMSO to form a stock of 20 μmol/L. UNC1999 was produced at the Icahn School of Medicine at Mount Sinai[25](#cas14207-bib-0025){ref-type="ref"} and was diluted in DMSO to a stock of 10 mmol/L. GSK126 was purchased from CHEMIETEK and was diluted in DMSO to a stock of 20 mmol/L.

2.2. RNA‐seq library construction and sequencing analysis {#cas14207-sec-0005}
---------------------------------------------------------

The MM cell lines, MM.1S and H929, were treated with or without TAS‐117 (0.5 μmol/L) for 24 hours. Total RNA was extracted using an RNeasy Plus Micro Kit (Qiagen). RNA concentrations and integrity were verified using Agilent 2100 Bioanalyzer. cDNA libraries were generated using a NEBNext Ultra RNA Library Prep Kit (New England BioLabs). Sequencing was performed using HiSeq1500 (Illumina) with a single‐read sequencing length of 60 bp. TopHat (version 2.0.13; with default parameters) was used for mapping to the reference genome (UCSC/hg19) from the University of California, Santa Cruz Genome Browser (<http://genome.ucsc.edu/>) with annotation data from iGenomes (Illumina). Levels of gene expression were then quantified as reads per kilobase of exon unit per million mapped reads (RPKM) using Cuffdiff (Cufflinks version 2.2.1; with default parameters). Overexpressed genes (\>1.5‐fold) in both MM.1S and H929 cells, after TAS‐117 treatment, are listed in Table [S1](#cas14207-sup-0002){ref-type="supplementary-material"}.

2.3. Gene ontology analysis {#cas14207-sec-0006}
---------------------------

Lists of overexpressed genes after the TAS‐117 treatment (\>1.5‐fold enrichment, shown in Table [S1](#cas14207-sup-0002){ref-type="supplementary-material"}) were analyzed for gene ontology with DAVID resources (database used for annotation, visualization and integrated discovery) (<http://david.abcc.ncifcrf.gov>).

2.4. ChIP assays {#cas14207-sec-0007}
----------------

In FOXO3 ChIP experiments, MM.1S and H929 cells (40 × 10^6^) were incubated with TAS‐117 (0.5 μmol/L) for 48 hours. Cells were harvested and washed with ice‐cold PBS. DNA and proteins were crosslinked by the addition of paraformaldehyde (PFA) to a final concentration of 1% at 25°C for 10 minutes. Cells were centrifuged, lysed in RIPA buffer (50 mmol/L Tris‐HCl, pH 8.0, 150 mmol/L NaCl, 2 mmol/L EDTA, pH 8.0, 1% NP‐40 substitute, 0.5% sodium deoxycholate and 0.1% SDS) supplemented with protease inhibitor cocktail (Roche), and then sonicated (ultrasonic homogenizer, MICROTEC). The soluble chromatin fraction was recovered, pre--cleared with sheep anti--mouse IgG Dynabeads (Thermo Fisher), and then immunoprecipitated at 4°C overnight with 5 μg anti--FOXO3 (clone D12: sc‐48348X, Santa Cruz). Immunoprecipitates were thoroughly washed. DNA was purified using the MinElute PCR purification kit (Qiagen). In the ChIP assay, quantitative PCR (qPCR) was performed with the Step One Plus real‐time PCR system using SYBR Premix ExTaq II (Tli RNase Plus) from Takara. Primers for the *EZH1* promoter regions, the FOXO3‐positive locus (*BIM*)[26](#cas14207-bib-0026){ref-type="ref"} and the FOXO3‐negative locus (*GAPDH*),[27](#cas14207-bib-0027){ref-type="ref"} are listed in Table [S2](#cas14207-sup-0003){ref-type="supplementary-material"}.

2.5. Statistical analysis {#cas14207-sec-0008}
-------------------------

The significance of differences was measured using an unpaired two‐tailed Student's *t* test or Welch's test, if unequal variances were examined. Tests were calculated using GraphPad Prism, version 7. Data are shown as the mean ± SD. Significance was taken at values of \**P* \< 0.05, \*\**P* \< 0.01 and \*\*\**P* \< 0.001. The combined effect of UNC1999 or GSK126 with TAS‐117 was analyzed by isobologram analysis using the CompuSyn software program to calculate the combination index (CI) (Table [S3](#cas14207-sup-0003){ref-type="supplementary-material"}) for each combination (ComboSyn, Inc[28](#cas14207-bib-0028){ref-type="ref"}).

Detailed methods for cell lines and cultures, cytotoxicity assay, immunoblot and immunofluorescence analyses, quantitative reverse transcription PCR (RT‐PCR), assays of apoptosis, and lentiviral vectors are detailed in the Supplementary Methods section.

2.6. Deposition of data {#cas14207-sec-0009}
-----------------------

RNA sequence data were deposited in the DNA Data Bank of Japan (DDBJ) (accession number: DRA008478).

3. RESULTS {#cas14207-sec-0010}
==========

3.1. UNC1999 enhances TAS‐117‐induced cytotoxicity in multiple myeloma cells {#cas14207-sec-0011}
----------------------------------------------------------------------------

We incubated a subset of MM cell lines with increasing concentrations of TAS‐117 for 48 hours to evaluate the cytotoxic effects of Akt inhibition. Seven cell lines with different genetic backgrounds were used. We found heterogeneity in the responsiveness of MM cell lines to Akt inhibition. TAS‐117 induced significant cytotoxicity in MM.1S, H929 and OPM2/BTZ cell lines (Figure [1](#cas14207-fig-0001){ref-type="fig"}A). We then examined whether a relationship exists between the sensitivity to Akt inhibition and the intrinsic levels of activated phospho‐Akt (p‐Akt). In accordance with previous findings,[10](#cas14207-bib-0010){ref-type="ref"}, [29](#cas14207-bib-0029){ref-type="ref"}, [30](#cas14207-bib-0030){ref-type="ref"} TAS‐117‐sensitive cell lines had high levels of activated Akt, phosphorylated at serine 473 (p‐Akt‐ser473) (Figure [1](#cas14207-fig-0001){ref-type="fig"}B), suggesting their dependency on the Akt pathway as a pro--survival stimulant. The high p‐Akt baseline correlated with sensitivity to Akt inhibition, except in KMS11 cell line, which had activated Akt with no sensitivity to TAS‐117 treatment. However, phosphorylation levels at threonine 308 (thr308), which weakly activate Akt, did not correlate with TAS‐117 sensitivity (Figure [1](#cas14207-fig-0001){ref-type="fig"}B). Of note, cells with high p‐Akt‐ser levels showed markedly lower levels of the tumor suppressor, *PTEN*, than cell lines with low p‐Akt‐ser levels (Figure [S1](#cas14207-sup-0001){ref-type="supplementary-material"}A), suggesting an inverse relationship between the responsiveness to the Akt inhibitor and the intrinsic level of *PTEN*. The bortezomib‐resistant cell line OPM2/BTZ, generated from parental OPM2 cells,[31](#cas14207-bib-0031){ref-type="ref"} had the highest p‐Akt levels, which were associated with the lack of *PTEN* expression (Figure [1](#cas14207-fig-0001){ref-type="fig"}B and Figure [S1](#cas14207-sup-0001){ref-type="supplementary-material"}A).

![UNC1999 enhances TAS‐117‐induced cytotoxicity in multiple myeloma (MM) cells. A, KMS11, KMS11/BTZ, RPMI8226, OPM2, OPM2/BTZ, MM.1S and H929 cells were treated with the indicated concentrations of TAS‐117, up to 10 μmol/L, for 48 h and the percentage of cell viability was assessed by the MTS assay relative to an untreated control. Data represent the mean ± SD of triplicates. B, Immunoblots for the basal expression of the indicated antibodies in the cell lines used in (A). GAPDH served as the loading control. C and D, MTS assay showing the viability of MM.1S (C) or H929 cells (D) after treatment with the indicated doses of UNC1999 "upper panels" or GSK126 "lower panels" for 72 h in combination with the indicated doses of TAS‐117 for the last 48 h, relative to the untreated control. Data represent the mean ± SD of triplicates. The calculation of the combination index for each combination is shown to the right of each graph. E, Flow cytometric analysis, using annexin V/PI staining, for MM.1S cells treated for 48 h with UNC1999 (5 μmol/L) and/or TAS‐117 (2 μmol/L) for the last 12 h](CAS-110-3695-g001){#cas14207-fig-0001}

Crosstalk between epigenetic modulators and signaling pathways has already been reported in some contexts.[14](#cas14207-bib-0014){ref-type="ref"}, [22](#cas14207-bib-0022){ref-type="ref"}, [23](#cas14207-bib-0023){ref-type="ref"}, [24](#cas14207-bib-0024){ref-type="ref"} Bisserier and Wajapeyee (2018) found that resistance to EZH2 inhibition in lymphoma cells may be acquired through the activation of the PI3K/Akt pathway, and the inhibition of PI3K sensitized resistant cancer cells to the cytotoxic effects of EZH2 inhibitors.[32](#cas14207-bib-0032){ref-type="ref"} Based on these findings, we treated myeloma cell lines with TAS‐117 in combination with either the dual EZH2/EZH1 inhibitor, UNC1999 (IC50, EZH2 \< 10 nmol/L; EZH1 45 nmol/L),[33](#cas14207-bib-0033){ref-type="ref"} or a selective EZH2 inhibitor, GSK126 (IC50, EZH2 9.9 nmol/L; EZH1 680 nmol/L).[34](#cas14207-bib-0034){ref-type="ref"} Interestingly, dual EZH2/EZH1 inhibition using UNC1999 enhanced the cytotoxicity induced by TAS‐117 more effectively than the selective EZH2 inhibitor, GSK126 (Figure [1](#cas14207-fig-0001){ref-type="fig"}C,D and Figure [S1](#cas14207-sup-0001){ref-type="supplementary-material"}B). The combination outcome was validated using CompuSyn software,[35](#cas14207-bib-0035){ref-type="ref"} calculating the CI. The analysis confirmed the synergism between UNC1999 and TAS‐117, achieving CI that was markedly lower than 1, in MM.1S (Figure [1](#cas14207-fig-0001){ref-type="fig"}C "right panels" and Table [S3](#cas14207-sup-0003){ref-type="supplementary-material"}A). In addition, in H929 and OPM2/BTZ cells, CI values for UNC1999 combination was synergistic (\<1) and comparatively lower than GSK126 combination values (Figure [1](#cas14207-fig-0001){ref-type="fig"}D, Figure [S1](#cas14207-sup-0001){ref-type="supplementary-material"}B "right panels" and Table [S3](#cas14207-sup-0003){ref-type="supplementary-material"}B,C). These results emphasize a crucial role for EZH1 inhibition besides EZH2 inhibition in MM. Of note, TAS‐117/UNC1999 combination was effective against TAS‐117‐sensitive cell lines, while TAS‐117‐resistant cell lines, such as OPM2 parent cells, showed no synergistic effect (Figure [S1](#cas14207-sup-0001){ref-type="supplementary-material"}C and Table [S3](#cas14207-sup-0003){ref-type="supplementary-material"}D). In an attempt to elucidate the mechanisms by which UNC1999 enhanced TAS‐117‐induced cytotoxicity in MM cells, we performed a flow cytometric analysis using annexin V/PI staining for single and combined treatments. We found that TAS‐117/UNC1999 combination increased the percentage of the annexin V‐positive apoptotic cell fraction more than UNC1999 or TAS‐117 alone (Figure [1](#cas14207-fig-0001){ref-type="fig"}E and Figure [S1](#cas14207-sup-0001){ref-type="supplementary-material"}D). Collectively, these results suggest that TAS‐117 inhibits the growth of myeloma cells and that dual EZH2/EZH1 inhibition synergizes with Akt inhibition through the induction of apoptosis.

3.2. TAS‐117 downregulates *EZH2* expression via E2F1 inactivation {#cas14207-sec-0012}
------------------------------------------------------------------

Previous studies have reported that *EZH2* expression may, context‐dependently, be regulated by different signaling pathways.[14](#cas14207-bib-0014){ref-type="ref"}, [22](#cas14207-bib-0022){ref-type="ref"}, [23](#cas14207-bib-0023){ref-type="ref"}, [24](#cas14207-bib-0024){ref-type="ref"} Therefore, we examined EZH2 mRNA and protein expression levels in MM.1S, H929 and OPM2/BTZ cell lines when Akt signaling was inhibited. TAS‐117 significantly downregulated EZH2 mRNA and its protein levels in the three responsive cell lines in concentration‐dependent (Figure [2](#cas14207-fig-0002){ref-type="fig"}A,B and Figure [S2](#cas14207-sup-0001){ref-type="supplementary-material"}A) and time‐dependent manners (Figure [2](#cas14207-fig-0002){ref-type="fig"}C and Figure [S2](#cas14207-sup-0001){ref-type="supplementary-material"}B), while H3K27me3 levels were maintained or elevated, suggesting a possible compensatory effect by EZH1 (Figure [2](#cas14207-fig-0002){ref-type="fig"}B,C). Moreover, *EZH2* mRNA levels were additively abolished after the combination of TAS‐117 and UNC1999 (Figure [2](#cas14207-fig-0002){ref-type="fig"}D). However, *EZH2* expression in the OPM2 parental cell line was not affected by TAS‐117 treatment, unlike the bortezomib‐resistant cell line (OPM2/BTZ) (Figure [S2](#cas14207-sup-0001){ref-type="supplementary-material"}C,D). Of note, while TAS‐117 significantly abolished p‐Akt levels (Figure [2](#cas14207-fig-0002){ref-type="fig"}B,C and Figure [S2](#cas14207-sup-0001){ref-type="supplementary-material"}A), it resulted in the feedback activation of the MAPK pathway, depicted by the upregulation of p‐ERK1/2 and phosphorylation of the PI3K regulatory subunit, p85 (Figure [S2](#cas14207-sup-0001){ref-type="supplementary-material"}E).

![TAS‐117 downregulates *EZH2* expression via E2F1 inactivation. A, Quantitative RT‐PCR analysis for *EZH2* mRNA expression in MM.1S "left panel" and H929 "right panel" cells treated with the indicated doses of TAS‐117 for 24 h. The *y*‐axis represents fold changes after the normalization to *GAPDH*, and error bars represent the SD of triplicates. Significance is indicated relative to the untreated control. The list for sequences of primers used for RT‐qPCR is described in Table [S4](#cas14207-sup-0003){ref-type="supplementary-material"}. B and C, Immunoblots for the indicated proteins in MM.1S and H929 cells treated with the indicated doses of TAS‐117 for 48 h (B) or 5 μmol/L of TAS‐117 for the indicated times (C). GAPDH, Akt and H3 served as loading controls. EZH2 and H3K27me3 amounts relative to GAPDH and H3, respectively, are shown. D, Quantitative RT‐PCR analysis for *EZH2* mRNA expression in MM.1S cells treated for 72 h with UNC1999 (5 μmol/L) and/or TAS‐117 (2 μmol/L) for the last 24 h. The *y*‐axis represents fold changes after the normalization to *GAPDH*, and error bars represent the SD of triplicates. Significance is indicated relative to the compared groups. E, Quantitative RT‐PCR analysis for *E2F1* (upper panel) and *E2F2* (lower panel) mRNA expression in MM.1S "left panel" and H929 "right panel" cells treated with the indicated doses of TAS‐117 for 24 h. The *y*‐axis represents fold changes after the normalization to *GAPDH*, and error bars represent the SD of triplicates. Significance is indicated relative to the untreated control. F, Immunoblots for the indicated proteins in MM.1S (left) and H929 (right) cells treated with the indicated doses of TAS‐117 for 48 h. α‐Tubulin served as the loading control. \**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001 by Student's *t*test](CAS-110-3695-g002){#cas14207-fig-0002}

To elucidate the mechanisms underlying *EZH2* downregulation, we focused on the retinoblastoma‐E2F (Rb‐E2F) complex, which transcriptionally regulates many proliferative pathways, including *EZH2*.[19](#cas14207-bib-0019){ref-type="ref"}, [36](#cas14207-bib-0036){ref-type="ref"}, [37](#cas14207-bib-0037){ref-type="ref"} We previously showed that E2F1 bound to the *EZH2* promoter and activated its expression in myeloma cells, and also that bortezomib treatment downregulated *EZH2* expression by abrogating *E2F1* expression.[19](#cas14207-bib-0019){ref-type="ref"} In the present study, TAS‐117 treatment induced marked downregulation of *E2F1* and *E2F2* mRNA and E2F1 protein expression (Figure [2](#cas14207-fig-0002){ref-type="fig"}E,F and Figure [S2](#cas14207-sup-0001){ref-type="supplementary-material"}F,G). To further clarify the mechanisms responsible for the *E2F1/2* downregulation/inactivation, we examined the levels of cyclins and cyclin‐dependent kinases (CDK), as these are direct targets of the PI3K/Akt cascade and, thus, regulate the phosphorylation of Rb and subsequent destabilization of the Rb‐E2F complex.[38](#cas14207-bib-0038){ref-type="ref"} We found that TAS‐117 abrogated cyclin D1, CDK1, CDK2 and phospho‐Rb levels with the marked upregulation of p27 (also known as CDKN1B) (Figure [2](#cas14207-fig-0002){ref-type="fig"}F and Figure [S2](#cas14207-sup-0001){ref-type="supplementary-material"}G). Collectively, these results confirm that inhibition of the Akt cascade regulates the expression of *EZH2* through the interaction/stabilization of the Rb‐E2F complex.

3.3. EZH1 compensates for the downregulation of EZH2 by Akt inhibition {#cas14207-sec-0013}
----------------------------------------------------------------------

Previous studies have suggested that EZH1 augments and complements EZH2 activity and partially compensates for its loss in different contexts.[17](#cas14207-bib-0017){ref-type="ref"}, [18](#cas14207-bib-0018){ref-type="ref"}, [20](#cas14207-bib-0020){ref-type="ref"}, [21](#cas14207-bib-0021){ref-type="ref"}, [39](#cas14207-bib-0039){ref-type="ref"} We herein demonstrated that H3K27me3 levels were maintained or elevated after TAS‐117 treatment (see the data in Figure [2](#cas14207-fig-0002){ref-type="fig"}B,C). This result prompted us to hypothesize that the function of EZH1 was augmented following Akt inhibition. RT‐qPCR and western blot analyses both confirmed that EZH1 was markedly upregulated after TAS‐117 treatment in time‐dependent and concentration‐dependent manners (Figure [3](#cas14207-fig-0003){ref-type="fig"}A‐C and Figure [S3](#cas14207-sup-0001){ref-type="supplementary-material"}A‐C) in the sensitive cell lines, unlike the TAS‐117‐resistant parental OPM2 cells (Figure [S3](#cas14207-sup-0001){ref-type="supplementary-material"}D).

![EZH1 compensates for the downregulation of EZH2 by Akt inhibition. A, Quantitative RT‐PCR analysis for *EZH1* mRNA expression in MM.1S "left panel" and H929 "right panel" cells treated with the indicated doses of TAS‐117 for 24 h. The *y*‐axis represents fold changes after the normalization to *GAPDH*, and error bars represent the SD of triplicates. Significance is indicated relative to the untreated control. B, Immunoblots for the indicated proteins in MM.1S and H929 cells treated with the indicated doses of TAS‐117 for 48 h. GAPDH and H3 served as loading controls. EZH1 and H3K27me3 amounts relative to GAPDH and H3, respectively, are shown. C, Quantitative RT‐PCR analysis for *EZH1* mRNA expression in MM.1S and H929 cells treated with TAS‐117 3 μmol/L for the indicated times. The *y*‐axis represents fold changes after the normalization to *GAPDH*, and error bars represent the SD of triplicates. Significance is indicated relative to the untreated control. \*\**P* \< 0.01; \*\*\**P* \< 0.001 by Student's *t* test](CAS-110-3695-g003){#cas14207-fig-0003}

Because *EZH1* was markedly upregulated after the inhibition of Akt, and EZH2 and EZH1 both complement each other for chromatin compaction and, hence, transcriptional silencing,[17](#cas14207-bib-0017){ref-type="ref"}, [18](#cas14207-bib-0018){ref-type="ref"} we hypothesized that the depletion of *EZH1* may enhance the sensitivity of myeloma cells to Akt inhibition. To this end, we transduced MM.1S and H929 with lentiviral shRNA against *EZH1*, which markedly abrogated EZH1 mRNA and protein expression (Figure [4](#cas14207-fig-0004){ref-type="fig"}A "left panel" and B) without the compensatory upregulation of *EZH2* (Figure [4](#cas14207-fig-0004){ref-type="fig"}A "right panel"). Of note, the *EZH1* level remained normal after *EZH2* knockdown (Figure [S3](#cas14207-sup-0001){ref-type="supplementary-material"}E,F). Importantly, *EZH1* knockdown significantly enhanced the sensitivity of myeloma cells to TAS‐117‐induced cytotoxicity (Figure [4](#cas14207-fig-0004){ref-type="fig"}C). As shown in Figure [2](#cas14207-fig-0002){ref-type="fig"}B, H3K27me3 levels were maintained or elevated after TAS‐117 treatment. This prompted us to investigate the changes in H3K27me3 levels in *shEZH1*‐transduced cells after TAS‐117 treatment. To achieve this, *EZH1*‐knockdown MM.1S cells were treated with TAS‐117 at a lower concentration, as cells became more sensitive to Akt inhibition. We found that H3K27me3 levels after TAS‐117 treatment were lower in *EZH1* knockdown cells than in *shLuc*‐transduced control cells (Figure [4](#cas14207-fig-0004){ref-type="fig"}D), coupled with the attenuated upregulation of *EZH1* mRNA from that in *shLuc* cells (Figure [4](#cas14207-fig-0004){ref-type="fig"}E), and the expected downregulation of *EZH2* mRNA (Figure [4](#cas14207-fig-0004){ref-type="fig"}F). Collectively, these results indicate that *EZH1* compensates for the downregulation of *EZH2* induced by Akt inhibition and the loss of *EZH1* expression sensitizes MM cells to Akt inhibition.

![*EZH1* knockdown sensitizes multiple myeloma (MM) cells to Akt inhibition. A, Quantitative RT‐PCR analysis for *EZH1* (left) and *EZH2* (right) mRNA expression in MM.1S and H929 cells transduced with shRNA lentiviral vectors against *EZH1* and luciferase. The *y*‐axis represents fold changes after the normalization to *GAPDH*, and error bars represent the SD of triplicates. Significance is indicated relative to the untreated control. B, Immunoblots for EZH1 and H3K27me3 in MM.1S and H929 cells transduced with shRNA lentiviral vectors against *EZH1* and luciferase. GAPDH and H3 served as loading controls. C, MTS assay showing the viability of MM.1S "left" or H929 "right" cells transduced with shRNA lentiviral vectors against *EZH1* and luciferase and treated with the indicated doses of TAS‐117 for 48 h, relative to the untreated control. Data represent the mean ± SD of triplicates. Significance is indicated relative to *shLuc*. D, Immunoblots for H3K27me3 in MM.1S cells transduced with shRNA lentiviral vectors against EZH1 and luciferase and treated with the indicated doses of TAS‐117 for 48 h. H3 served as the loading control. E and F, Quantitative RT‐PCR analysis for *EZH1* (E) and *EZH2* (F) mRNA expression in MM.1S cells transduced with shRNA lentiviral vectors against *EZH1* and luciferase and treated with the indicated doses of TAS‐117 for 24 h. The *y*‐axis represents fold changes after the normalization to *GAPDH*, and error bars represent the SD of triplicates. All groups were normalized to *shLuc*‐untreated group. Significance is indicated relative to the compared groups. \**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001; ns, not significant by Student's *t* test](CAS-110-3695-g004){#cas14207-fig-0004}

3.4. FOXO3 regulates *EZH1* promoter in response to TAS‐117 treatment {#cas14207-sec-0014}
---------------------------------------------------------------------

To clarify the molecular mechanisms underlying *EZH1* upregulation after TAS‐117 treatment in myeloma cells, we performed RNA sequencing for MM.1S and H929 cells treated with 0.5 μmol/L of TAS‐117 for 24 hours. We conducted KEGG pathway analysis (using DAVID bioinformatics database)[40](#cas14207-bib-0040){ref-type="ref"} on genes that were upregulated (\>1.5‐fold) from those in untreated control cells (Figure [5](#cas14207-fig-0005){ref-type="fig"}A and Figure [S4](#cas14207-sup-0001){ref-type="supplementary-material"}A) (1281 genes in MM.1S and 1145 genes in H929, (Table [S1](#cas14207-sup-0002){ref-type="supplementary-material"})). Among significantly enriched pathways, such as MAPK and NF‐κB pathways, FOXO signaling pathway showed the highest enrichment (*P*‐value \< 2.1^−08^) (Figure [5](#cas14207-fig-0005){ref-type="fig"}A and Figure [S4](#cas14207-sup-0001){ref-type="supplementary-material"}A). We focused on the FOXO pathway as it is a crucial target in MM treatment using PI3K/Akt pathway inhibitors.[41](#cas14207-bib-0041){ref-type="ref"} RT‐qPCR confirmed the upregulation of the well‐established downstream targets of FOXO TF, *CDKN1B* and *BIM*,[7](#cas14207-bib-0007){ref-type="ref"} after TAS‐117 treatment (Figure [5](#cas14207-fig-0005){ref-type="fig"}B and Figure [S4](#cas14207-sup-0001){ref-type="supplementary-material"}B). We focused on FOXO3 as it was the main *FOXO* family gene expressed in MM cells according to our RNA‐seq data, besides its role in MM therapy.[41](#cas14207-bib-0041){ref-type="ref"} Akt phosphorylates FOXO3, thereby excluding it to the cytoplasm, and, hence, restricts its transcriptional activity.[7](#cas14207-bib-0007){ref-type="ref"} We examined the nuclear localization of FOXO3 following TAS‐117 treatment by immunostaining, and found that TAS‐117 significantly enhanced the nuclear accumulation of FOXO3 in MM.1S and H929 cell lines, as depicted by both the immunostaining images (Figure [5](#cas14207-fig-0005){ref-type="fig"}C and Figure [S4](#cas14207-sup-0001){ref-type="supplementary-material"}C) and the digital calculations of the nuclear subset of FOXO3 in the TAS‐117‐treated group versus the untreated control (Figure [5](#cas14207-fig-0005){ref-type="fig"}D). FOXO3 regulates its own promoter.[42](#cas14207-bib-0042){ref-type="ref"} Indeed, *FOXO3* and *FOXO4* were also upregulated after TAS‐117 treatment (Figure [5](#cas14207-fig-0005){ref-type="fig"}B and Figure [S4](#cas14207-sup-0001){ref-type="supplementary-material"}B).

![FOXO3 regulates the *EZH1* promoter in response to the TAS‐117 treatment. A, Gene ontology analysis (KEGG pathway) of the enriched gene list in H929 cells (\>1.5‐fold) after the treatment with TAS‐117 (0.5 μmol/L) for 24 h, using DAVID Bioinformatics Resources. Bars represent −log~2~ of *P*‐values for the corresponding pathway. B, Quantitative RT‐PCR analysis for *FOXO3*, *FOXO4*, *BIM* and *CDKN1B* mRNA expression in H929 cells treated with TAS‐117 (1 μmol/L) for 24 h. The *y*‐axis represents fold changes after the normalization to *GAPDH*, and error bars represent the SD of triplicates. Significance was indicated relative to the untreated control. C, Immunofluorescence staining of the anti--FOXO3 antibody in H929 cells treated with or without TAS‐117 at 0.5 μmol/L for 24 h, using Jurkat cells as a positive control. H929 cells lacking the primary antibody treatment were used as a negative control (NC). D, Digital representation of the average fluorescence intensity of the FOXO3 nuclear fraction in MM.1S and H929 cells treated with or without TAS‐117 at 0.5 μmol/L for 24 h. Significance is indicated relative to the untreated control. E, Schematic representation of the location of the primer sets for the human *EZH1* promoter region. F, ChIP‐qPCR analysis for FOXO3 occupancy on the *EZH1* promoter in MM.1S "upper" and H929 "lower" cells treated with or without 0.5 μmol/L of TAS‐117 for 24 h. *BIM* and *GAPDH* promoters were used as positive and negative controls, respectively. Values correspond to the mean percentage of the input enrichment ± SD of triplicate qPCR reactions. Primer sequences for *EZH1*, *BIM* and *GAPDH* promoters are available in Table [S2](#cas14207-sup-0003){ref-type="supplementary-material"}. Significance is indicated relative to the untreated control. G, Quantitative RT‐PCR analysis for *FOXO3* and *EZH1* mRNA expression in H929 cells transduced with shRNA lentiviral vectors against *FOXO3* (*shFOXO3*) and control (*shScramble*) *CDKN1B* was used as the positive target for FOXO3. The *y*‐axis represents fold changes after the normalization to *GAPDH*, and error bars represent the SD of triplicates. Significance is indicated relative to *shScramble*. \**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001 by Student's *t* test, except D, for which Welch's test was used](CAS-110-3695-g005){#cas14207-fig-0005}

In four different murine studies that analyzed the binding sites of Foxo TF,[43](#cas14207-bib-0043){ref-type="ref"} 461 common genes, including the *Ezh1* promoter, were identified to have prominent Foxo peaks, in neuronal progenitors,[44](#cas14207-bib-0044){ref-type="ref"} Tregulatory cells,[45](#cas14207-bib-0045){ref-type="ref"} CD8^+^ cells[46](#cas14207-bib-0046){ref-type="ref"} and pre--B cells,[47](#cas14207-bib-0047){ref-type="ref"} suggesting that Foxo TF share some common target genes in different contexts. Based on this observation, we hypothesized that FOXO3 may be a regulatory partner for the human *EZH1* gene in myeloma cells in response to TAS‐117 treatment. To this end, we analyzed Foxo‐binding loci on the mouse *Ezh1* promoter in the previously mentioned studies. We found that they shared similar Foxo‐binding peaks spanning approximately 160 bp upstream to 300 bp downstream of the *Ezh1* transcription start site (TSS) (Figure [S4](#cas14207-sup-0001){ref-type="supplementary-material"}D). FOXO TF are characterized by their conserved DNA‐binding domain,[7](#cas14207-bib-0007){ref-type="ref"} and more than 80% of FOXO3‐binding sites share the common consensus binding motif GTAAACAA.[48](#cas14207-bib-0048){ref-type="ref"} Interestingly, this binding motif was found both in human *EZH1* (+48 from the TSS) and mouse *Ezh1* (+77 from the TSS) promoter regions corresponding to the Foxo peaks observed in the murine studies data (Figure [S4](#cas14207-sup-0001){ref-type="supplementary-material"}E). We designed two primers for the human *EZH1* promoter to investigate whether FOXO TF regulates *EZH1* promoter in response to TAS‐117 treatment (Figure [5](#cas14207-fig-0005){ref-type="fig"}E). We then performed ChIP followed by quantitative PCR on TAS‐117‐treated and TAS‐117‐untreated cells. TAS‐117 promoted the binding of FOXO3 to the *EZH1* promoter, in addition to one of the canonical FOXO3 targets, the *BIM* promoter, in MM.1S and H929 cells (Figure [5](#cas14207-fig-0005){ref-type="fig"}F). To further confirm our results, we expressed shRNA against *FOXO3*, *shFOXO3* and control, *shScramble*, in H929 cells using lentiviral vectors. The knockdown of *FOXO3* induced the downregulation of *EZH1* mRNA in addition to *CDKN1B*, as a common target of FOXO3 (Figure [5](#cas14207-fig-0005){ref-type="fig"}G). Moreover, as reported in primary hematopoietic cells,[49](#cas14207-bib-0049){ref-type="ref"} *FOXO3* knockdown attenuated the growth of MM cells (Figure [S4](#cas14207-sup-0001){ref-type="supplementary-material"}F). Collectively, these results provide a regulatory mechanism for the activation of *EZH1* transcription after Akt inhibition, which was mediated by FOXO3 TF.

4. DISCUSSION {#cas14207-sec-0015}
=============

We herein investigated the molecular interactions between the PI3K/Akt cascade and the catalytic components of PRC2, EZH2 and EZH1, and demonstrated that a "dual" EZH2/EZH1 inhibitor, UNC1999, but not "selective" EZH2 inhibitor GSK126, exerted synergistic anti--myeloma effects when combined with the Akt inhibitor, TAS‐117. This combination has potential as a therapeutic option for a broad range of myeloma patients because in addition to the basal activation of Akt in myeloma cells, not only the interaction with bone marrow stromal cells but also the response to the conventional anti--myeloma therapy, namely, proteasome inhibitors, results in the further activation of Akt.[10](#cas14207-bib-0010){ref-type="ref"}

Several TF have been reported to bind and regulate the *EZH2* promoter, including MAPK/PI3K pathways through their downstream Elk1[22](#cas14207-bib-0022){ref-type="ref"} or activator protein 1 (AP‐1),[24](#cas14207-bib-0024){ref-type="ref"} KRAS mutations via ERK or Akt,[23](#cas14207-bib-0023){ref-type="ref"} and NF‐κB.[14](#cas14207-bib-0014){ref-type="ref"} We previously demonstrated that E2F1 activity was closely associated with the downregulation of *EZH2* in MM in response to bortezomib treatment.[19](#cas14207-bib-0019){ref-type="ref"} E2F is inactivated through the formation of an inactive complex with Rb. In contrast, Akt activates cyclins and cyclin‐dependent kinases (CDK), which, in turn, hyper‐phosphorylate Rb, thereby inducing the release and activation of E2F.[50](#cas14207-bib-0050){ref-type="ref"} In the present study, TAS‐117 induced the upregulation of *CDKN1B*, through FOXO upregulation,[7](#cas14207-bib-0007){ref-type="ref"} in addition to the inactivation of cyclins and CDK and, hence, hypo‐phosphorylated Rb, thereby stabilizing the Rb‐E2F1 complex and diminishing free E2F1 available for binding to its target genes, including its own promoter[51](#cas14207-bib-0051){ref-type="ref"} and the *EZH2* promoter.[19](#cas14207-bib-0019){ref-type="ref"}, [36](#cas14207-bib-0036){ref-type="ref"}, [37](#cas14207-bib-0037){ref-type="ref"}

In contrast to these insights into *EZH2* transcriptional regulation, the transcriptional regulation of *EZH1* has not yet been fully clarified. Extensive ChIP‐seq analyses of FOXO TF‐binding targets[43](#cas14207-bib-0043){ref-type="ref"} revealed that a significant number of genes, including the *Ezh1* promoter, were "core‐bound" by Foxo1 and Foxo3 in four different murine studies.[43](#cas14207-bib-0043){ref-type="ref"}, [44](#cas14207-bib-0044){ref-type="ref"}, [45](#cas14207-bib-0045){ref-type="ref"}, [46](#cas14207-bib-0046){ref-type="ref"}, [47](#cas14207-bib-0047){ref-type="ref"} Akt phosphorylates FOXO3 and promotes its nuclear exit,[7](#cas14207-bib-0007){ref-type="ref"} thereby diminishing its transcriptional activity, including its own regulation.[42](#cas14207-bib-0042){ref-type="ref"} Consistent with these findings, we found that TAS‐117 enhanced FOXO3 nuclear accumulation in myeloma cells and, interestingly, increased the binding of FOXO3 to the *EZH1* promoter, thereby controlling *EZH1* compensatory upregulation. To the best of our knowledge, this is the first study to show a regulatory mechanism for *EZH1* transcription in MM. Collectively, the present study supports the theory that histone modifications are part of conventional signaling cascades under context‐dependent control. Based on the present results, we propose *EZH2* and *EZH1* as eventual components of the PI3K/Akt pathway and E2F1 and FOXO3 as intermediate nuclear effectors with the ability to regulate *EZH2* and *EZH1* transcription, respectively.

Despite the development of selective EZH2 inhibitors in clinical trials, it is clear that the inhibition of EZH2 alone is insufficient for the complete disruption of PRC2 oncogenic functions.[19](#cas14207-bib-0019){ref-type="ref"}, [20](#cas14207-bib-0020){ref-type="ref"}, [21](#cas14207-bib-0021){ref-type="ref"} Although inconsequential to EZH2 functions, EZH1 can augment and maintain PRC2 activities.[17](#cas14207-bib-0017){ref-type="ref"}, [18](#cas14207-bib-0018){ref-type="ref"}, [39](#cas14207-bib-0039){ref-type="ref"} We herein clearly demonstrated that EZH1 contributes to an important compensatory mechanism in MM. While *EZH2* was abrogated after TAS‐117 treatment, *EZH1* was markedly upregulated with the retention of H3K27me3. Therefore, the combination with dual EZH2/EZH1 inhibition using UNC1999 was more effective than with selective EZH2 inhibition using GSK126. We previously reported that the combination of bortezomib with UNC1999 exerted superior cytotoxic effects to that with GSK126 against PRC2‐dependent cancers, MM and prostate cancer.[19](#cas14207-bib-0019){ref-type="ref"} EZH1 has an undeniable role in the maintenance of cancer‐initiating cells. Nakagawa and colleagues recently clarified the intimate role of EZH1 in addition to EZH2 in the maintenance of myeloma stem cells,[20](#cas14207-bib-0020){ref-type="ref"} proposing that the inhibition of both EZH2 and EZH1 is crucial for the eradication of myeloma stem cells. This was further supported by the evidence showing that the deletion of both *Ezh1* and *Ezh2* had more significant effects than the deletion of *Ezh2* alone in eradicating quiescent leukemia stem cells.[21](#cas14207-bib-0021){ref-type="ref"} These findings and the present results emphasize the crucial role of the inhibition of EZH1 as well as EZH2 for effective cancer treatment and that a significant portion of myeloma patients will benefit from the combination of TAS‐117 with dual EZH2/EZH1 inhibition.

The responsiveness of myeloma cells to Akt inhibition is linked to the basal level of Akt activation.[10](#cas14207-bib-0010){ref-type="ref"}, [29](#cas14207-bib-0029){ref-type="ref"} We herein showed that TAS‐117 sensitivity was not only associated with high p‐Akt levels but also with low/deleted *PTEN* levels, and cells with high *PTEN* levels were more resistant to Akt inhibition. Furthermore, MAPK activation constitutes an apparent intrinsic resistance mechanism to Akt inhibition in MM.[10](#cas14207-bib-0010){ref-type="ref"}, [29](#cas14207-bib-0029){ref-type="ref"}, [30](#cas14207-bib-0030){ref-type="ref"} Dynamic crosstalk between the PI3K/Akt and MEK/ERK pathways may eventually play a role in modulating the resistance of MM cells to the inhibition of a single pathway. Either pathway can regulate the other through several overlapping inhibitory feedback mechanisms; relieving one feedback may secondarily activate the other pathway.[52](#cas14207-bib-0052){ref-type="ref"} One of the most important downstream targets of Akt is mTORC1. The phosphorylation of mTORC1 inhibits S6K/IRS1 axis and triggers a brake on PI3K activity, thereby negatively regulating Akt activity. The inhibition of Akt/mTORC1 relieves this feedback and activates PI3K,[53](#cas14207-bib-0053){ref-type="ref"} which, in turn, activates RAS and then feeds into the activation of MEK/ERK cascade.[54](#cas14207-bib-0054){ref-type="ref"} In contrast, Akt inhibition‐mediated FOXO pathway activation promotes FOXO‐driven transcription of several receptor tyrosine kinases, leading to stronger PI3K/MEK/ERK activation.[52](#cas14207-bib-0052){ref-type="ref"} In the present study, we observed the activation of MAPK, depicted by increases in p‐ERK1/2 levels, after TAS‐117 treatment, which was similarly reported in MM using different allosteric Akt inhibitors,[10](#cas14207-bib-0010){ref-type="ref"}, [29](#cas14207-bib-0029){ref-type="ref"}, [30](#cas14207-bib-0030){ref-type="ref"} with the concurrent phosphorylation of PI3K regulatory subunit p85, and, hence, PI3K activation. Notably, UNC1999, a dual EZH1/2 inhibitor, overcame the effects of these resistance‐inducing pathways in Akt inhibition (data not shown), supporting its potential as a companion drug of Akt inhibitors.

In conclusion, the present results defined novel signaling‐epigenetic crosstalk between the PI3K/Akt pathway and the PRC2 components, EZH2 and EZH1, and demonstrated that Akt inhibition modulates *EZH2* and *EZH1* levels via the Akt downstream effectors E2F1 and FOXO3, respectively. Therefore, targeting both EZH2 and EZH1 in addition to Akt inhibition may be a promising means to eradicate MM, leading to significant advances in treatment.
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